Description

This published Phase I/II clinical study led by Dr. Victor Seledtsov of the Novosibirsk Immunotherapy Center in Russia - http://www.transplantation.ru showed that patients in late stage melanoma had more positive outcomes after receiving subcutaneous administration of xenogenic polyantigenic vaccine (XPV) prepared from disrupted murine melanoma compared to the control group which received traditional treatment.

More information on the Novosibirsk Immunotherapy Center in Russia can be found on the Repair Stem Cell Institute website.